SEARCH

SEARCH BY CITATION

Keywords:

  • Antimicrobials;
  • antifungals;
  • antiviral;
  • drug interactions;
  • immunosuppressants;
  • organ transplant
Abbreviations
AUC

area under the curve

AZA

azathioprine

CSA

cyclosporine

CYP

cytochrome P450

ECMS

enteric coated mycophenolate sodium

EVR

everolimus

HCV

hepatitis C

HIV-1

human immunodeficiency virus

mTOR

mammalian target of rapamycin

MMF

mycophenolate mofetil

SRL

sirolimus

TAC

tacrolimus

Introduction

  1. Top of page
  2. Introduction
  3. Interactions That Significantly Raise Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  4. Interactions That Significantly Decrease Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  5. Acknowledgments
  6. Disclosures
  7. References

Infectious diseases are among the leading complications of immunosuppression for solid organ transplantation [1]. The first few months posttransplant are particularly critical because immunosuppression is usually at high levels, acute rejection episodes are most likely to occur during this time frame requiring further increases in immunosuppression, and patients are receiving anti-infective prophylaxis [2]. However, it is essential for the clinician to consider drug interactions and infectious complications for the life of the recipient. Although the risk of infection is highest in the first year posttransplant, the risk of infection may increase at any time during the posttransplant course when the patient's cumulative immunosuppressive state is enhanced (e.g. during treatment of rejection episodes when immunosuppression is intensified; Ref. [3]). In addition, infectious diagnosis may be complicated by lack of signs and symptoms of inflammation, alterations in anatomy as a result of transplant surgery, denervation of the transplanted graft and preexisting diseases [4]. Optimal treatment of specific infections, therefore, should be guided not only by knowledge of the pathogen's susceptibility to antimicrobial agents but also by the effects the agents will have on the pharmacokinetics and/or pharmacodynamics of the immunosuppressants that the patient is receiving.

Drug–drug interactions with immunosuppressants and anti-infective agents can be divided into two categories: pharmacokinetic and pharmacodynamic interactions. Pharmacokinetic drug–drug interactions may lead to altered drug concentrations of immunosuppressants, anti-infective agents or their metabolites through interactions in stages of absorption, distribution, metabolism or elimination. Some of the more frequently used immunosuppressive agents used in organ transplantation are metabolized via the cytochrome (CYP) 3A4 system. For example, immunosuppressive drug interactions can be caused by an anti-infective agent directly inhibiting CYP3A4 or via drug competition for CYP3A4 substrate sites. Both of these mechanisms may result in increased immunosuppressive concentrations. In contrast, CYP3A4 induction via increased synthesis or decreased breakdown of CYP isoenzymes may result in decreased immunosuppressive concentrations [5] Another type of interaction is through the membrane transporter P-glycoprotein [6]. Drugs that inhibit or induce P-glycoprotein activity can ultimately result in increased or decreased bioavailability in the intestine. Moreover, due to genetic polymorphisms, patients may express variation in CYP3A4 enzymes and P-glycoprotein, which also can influence drug levels. The reader is referred to the following published reviews for a more detailed review of the pharmacokinetic principles of immunosuppressive agents and mechanisms of drug–drug interactions [5, 6].

Pharmacodynamic interactions may occur as a result of drugs increasing or decreasing the efficacy or toxicity of each other. This may lead to detrimental or beneficial drug interactions. For example, the administration of calcineurin inhibitors with aminoglycosides, amphotericin, cidofovir, foscarnet, intravenous acyclovir or higher dose sulfamethoxazole-trimethoprim may result in the detrimental effect of additive nephrotoxicity. Alternative therapies without nephrotoxicity should be used whenever possible. When nephrotoxic therapies are essential to treatment, calcineurin inhibitors should be minimized whenever possible. Renal function must be carefully monitored and changes in renal function may necessitate decreasing or discontinuing anti-infective therapies.

Administration of mycophenolate mofetil (MMF), enteric coated mycophenolate sodium (ECMS) or azathioprine (AZA) with leflunomide for BK virus nephropathy may result in additive myelosuppression. Therefore, these antiproliferative agents should be discontinued upon initiation of leflunomide. Antiviral agents such as ganciclovir and valganciclovir and antibacterials such as linezolid and sulfonamides may result in myelosuppression when combined with MMF, ECMS or AZA too. Careful monitoring of white blood cells, platelets and hematocrit is necessary as well as consideration of dose adjustments of immunosuppressive and anti-infective agents as applicable. Pharmacodynamic interactions may also work in synergy. For example, CSA, (but not TAC) has been shown to inhibit hepatitis C virus in vitro, and may have a beneficial effect when combined with antiviral therapy [7]. In addition, the mTOR inhibitors may decrease the incidence and severity of cytomegalovirus posttransplant [8] and MMF has been reported to potentially be associated with a decreased incidence of Pneumocystis jiroveci pneumonia [9, 10].

Another consideration in dosing anti-infective agents is that many are renal-eliminated. Doses may need to be continually adjusted to maximize efficacy and limit toxicity, particularly in patients with fluctuating renal function. It is important to note that although MDRD is available to estimate GFR in transplant recipients, renal drug dosing recommendations are still based on Cockcroft-Gault calculations unless otherwise specified in the product information [11].

Table 1 provides summary information on interactions between anti-infectives and immunosuppressants, an indication of their severity, suggested actions by the clinician, the weight of evidence supporting these effects and suggested actions. For completeness, we have also included anti-infective agents in the table that may not always result in significant interactions in clinical practice, but have either in vitro data showing an interaction with immunosuppressants, or case reports showing evidence of an interaction. The following discussion describes these interactions in more detail focusing on the most severe and suggests approaches to alternative treatment.

Interactions That Significantly Raise Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels

  1. Top of page
  2. Introduction
  3. Interactions That Significantly Raise Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  4. Interactions That Significantly Decrease Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  5. Acknowledgments
  6. Disclosures
  7. References

Macrolide antibiotics

All macrolide antibiotics, with the exception of azithro-mycin, are moderate to strong inhibitors of CYP3A4 and thus decrease the metabolism of calcinerin inhibitors: cyclosporine (CSA) and tacrolimus (TAC), and mammalian target of rapamycin (mTOR) inhibitors: sirolimus (SRL) and everolimus (EVR; Ref. [12]). The magnitude of this effect varies between the macrolides, with erythromycin and clarithromycin having the greatest impact. Variations in immunosuppressive agent drug half-life can also impact the duration of the interaction. For example, SRL is dosed once daily and has a longer half live than EVR or calcineurin inhibitors, which are often dosed twice daily. In all cases, however, these combinations result in very significant (3- to 10-fold) increases in immunosuppressant concentration or area under the curve (AUC). The availability of clarithromycin and azithromycin, which have fewer gastrointestinal side effects, has resulted in diminished use of erythromycin in the community, thereby diminishing the chance of inadvertent co-administration. However, some surgical and medical intensive care units have adopted the use of erythromycin for gastrointestinal motility in patients with poor gastric emptying or ileus. The co-administration of erythromycin with calcineurin inhibitors, and especially mTOR inhibitors should be avoided in this situation when feasible; however, if the combination is used, at least a 50% reduction of calcineurin inhibitors should be considered early, because the effect is rapid. Daily drug level monitoring with calcineurin inhibitors is recommended and every third day level monitoring with mTOR inhibitors is recommended. Similar considerations apply to clarithromycin, which is widely used in the community and may be required for the treatment of transplant recipients with nontuberculous mycobacterial infections. However, this agent should be avoided whenever possible due to the interactions previously noted. The majority of in vitro and in vivo data indicate there is no pharmacokinetic interaction between azithromycin and calcineurin inhibitors or mTOR inhibitors. However, two case reports describe elevation of CSA concentrations with several days of concomitant administration of azithromycin [13, 14]. Elevation of TAC levels have also been reported with co-administered azithromycin [15]. Therefore, monitoring drug levels may be appropriate.

Antifungal agents

All of the azole derivative antifungal agents decrease the metabolism of calcineurin inhibitors and mTOR inhibitors resulting in modest to profound increases in serum concentration and AUC. The potency of the interaction is different for each agent. For example, itraconazole and posaconazole have been shown to be more-potent inhibitors of CYP3A4 than are fluconazole or voriconazole [16].

Ketoconazole has also been shown to be the most potent inhibitor of CYP3A4 and has been co-administered with calcineurin inhibitor or mTOR inhibitor based immunosuppression in an effort to decrease immunosuppressive dose requirements and cost to transplant recipients [17-20]. If undertaken, this drug combination must be carefully monitored as inadvertent discontinuation of ketoconazole by the patient or an outside health provider will dramatically decrease immunosuppressive levels.

The interaction of fluconazole with calcineurin inhibitors is both dose-dependent and drug-dependent [21]. At modest doses (100–200 mg/day) of fluconazole used for nonsystemic candidiasis, effects on CSA are minor, whereas moderate to significant increases are seen with TAC. At doses of fluconazole required for systemic fungal infection (e.g. 400 mg for cryptococcosis or candidemia) significant dose reductions of immunosuppressants are required.

Voriconazole prescribing information recommends empiric dose reduction of TAC by two-thirds and CSA by 50% of the original maintenance dose when voriconazole is initiated [21-23]. The combination of voriconazole and SRL is contraindicated as SRL levels may rapidly rise 10-fold [23]. However, a small case series reported that voriconazole and SRL could potentially be used together if low doses of SRL are used (0.5–1.0 mg/day; Ref. [24]). Similarly, EVR prescribing information recommends that it not be administered with voriconazole [25], but case reports have detailed their concurrent use with EVR dose reduction [26, 27]. Like voriconazole, posaconazole prescribing information also recommends empiric dose reduction of TAC by two-thirds and to decrease CSA dose by one-fourth of the original maintenance dose when posaconazole is initiated [28, 29]. The combination of posaconazole and SRL is contraindicated as SRL rise 9-fold [28, 30]. No information is available on the use of EVR and posaconazole in prescribing information of either agent [25, 28], but one case report in a renal transplant recipient found a 3.8-fold increase in everolimus levels with posaconazole [26]. Close drug monitoring is recommended at initiation, during and after discontinuation of voriconazole or posaconazole.

In addition, oral clotrimazole troches used for oral mucocutaneous candidiasis prophylaxis or treatment has also been shown to increase TAC blood levels significantly, doubling levels in some studies [31-34]. The mechanism of this interaction is thought to be related to cytochrome (CYP) 3A4. Calcineurin inhibitor and m TOR inhibitor levels should all be monitored during initiation or discontinuation of clotrimazole.

The new echinocandin antifungal agents provide alternatives to the use of azole derivatives. None of the echinochandins are significantly metabolized by CYP3A and are available only in intravenous formulations. Although the original studies that resulted in approval of caspofungin suggested increased hepatotoxicity when used in conjunction with CSA, and noted that CSA increase caspofungin AUC by 35% [35], subsequent studies found no significant increase in hepatotoxicity nor a major change in CSA or TAC pharmacokinetics [36, 37]. A previous review article also noted that TAC AUC, peak and 12 hour concentrations are decreased by 20% in presence of caspofungin [38], but current product information for caspofungin recommends to follow standard TAC dosing and level monitoring and has no interaction with the active metabolites of MMF either [35]. No data are available on interactions with mTOR inhibitors. Micafungin has not been shown to interact with TAC [39]. The micafungin product information notes that there was no effect of a single dose or multiple doses of micafungin on MMF, prednisolone, TAC or CSA [40]. However, one study has shown micafungin to decrease CSA concentrations by 16% in one study and hence monitoring of CSA levels is recommended [41]. Micafungin product information also notes that SRL AUC was increased by 21% with no effect on maximum concentration, in the presence of steady-state and recommends SRL dose monitoring with dose adjustment as needed [40]. A 22% increase in anidulafungin concentrations and drug exposure has been observed with CSA, but is not considered to be clinically relevant, and dose adjustments are not recommended for either agent [42]. Of note, this interaction has not been observed with anidulafungin and tacrolimus [43]. No data are available regarding interactions with mTOR inhibitors.

Antiretroviral agents

Patients chronically infected with human immunodeficiency virus-1 (HIV-1) are increasingly being transplanted for end organ disease [44]. Many of the antiretroviral medications are substrates of CYP3A4; therefore, the interactions between these medications can be severe, particularly when used with calcineurin inhibitors or mTOR inhibitors in combination with protease inhibitors [45]. All HIV-1 infected transplant recipients need close monitoring of immunosuppression levels to avoid underimmunosuppression or toxicity related to these medications. A summary of these interactions is provided in Table 1, but the reader is referred to the chapter in these guidelines on Solid Organ Transplant in the HIV-Infected Patient for further specific information on outcomes and drug interactions.

HCV protease inhibitors

The hepatitis C virus (HCV) protease inhibitors, boceprevir and telaprevir, are important new therapies for HCV treatment and are likely to be increasingly used in the liver transplant population. Both drugs are substrates and inhibitors of CYP3A4, with the main effect being elevated blood levels of the calcineurin inhibitors in healthy volunteers [46-48]. Empiric CSA dose reduction of 75% or holding calcineurin inhibitors when boceprevir or telaprevir are introduced with drug level monitoring has been recommended by some authors [47]. However, in three liver transplant recipients receiving co-administered CSA and boceprevir, only a minor increase in CSA blood levels were noted [49]. A series of six liver transplant patients treated with telepravir required dosing of TAC once weekly or EVR every three days with close monitoring of drug levels [50]. It seems based on several small case series in liver transplant recipients that boceprevir and telaprevir can be safely given with concomitant calcineurin inhibitors with close monitoring of drug levels [49-53]. No data are yet available on the use of SRL with HCV protease inhibitors, but drug interactions are expected to be similar to those with TAC [47].

Interactions That Significantly Decrease Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels

  1. Top of page
  2. Introduction
  3. Interactions That Significantly Raise Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  4. Interactions That Significantly Decrease Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  5. Acknowledgments
  6. Disclosures
  7. References

Rifamycins

All of the rifamycins are strong inducers of CYP3A4. For rifampin and rifabutin, clinical data confirm the dramatic increases in clearance and resultant decreases in plasma levels of the calcineurin inhibitors and mTOR inhibitors [54-60]. This effect has been reported to remain even in the presence of multiple CYP3A4 inhibiting medications [61]. No data are available for rifapentine but a similar effect is likely. This combination should be avoided if at all possible because of the severe difficulty of maintaining therapeutic levels of calcineurin inhibitors, mTOR inhibitors. In those situations where a rifamycin derivative must be used, as in patients with tuberculosis, increased doses of calcineurin inhibitors or mTOR inhibitors should be initiated with onset of combined therapy. A twofold dose increase is recommended at the initiation of therapy, with rapid subsequent increases (up to 10-fold reported) and frequent drug level monitoring until stable dosing is achieved. Similar vigilance is required when rifamycin therapy is discontinued.

A much less dramatic effect on MMF pharmacokinetics has been reported with rifampin [62]. Although the increase in MMF dosing requirements seems to be moderate compared with those for calcineurin inhibitors, the manufacturer's prescribing information recommends avoiding this combination when possible and monitoring drug levels closely if it is used [63]. There is no information available for use with ECMS [64], but based on the mechanism of interaction, we recommend closely monitoring drug levels if used. Of note, ethambutol and isoniazid, which are sometimes used in combination with these agents, do not seem to interact with immunosuppressive agents.

Artemether/lumefantrine

The artemether component of the new antimalarial artemether/lumefantrine is an inducer of CYP3A4 [65]. Although there is no currently available data on drug–drug interactions with immunosuppressants, it would be expected to potentially decrease calcineurin levels, as well as mTOR inhibitor levels (Table 1).

Table 1. Antiinfective drug interactions
  Severity of  Weight of
AntimicrobialImmunosuppressant1interaction2InteractionSuggested actionsevidence3
  1. Drugs in bold are contraindicated.

  2. 1CSA = cyclosporine; TAC = tacrolimus; SRL = sirolimus; EVR = everolimus; Imm = immunosuppressant; MMF = mycophenolate mofetil; ECMS = enteric-coated mycophenolate sodium; AZA = azathioprine. Note: Data on EVR not always present, but included in table on basis of similar route of metabolism to other immunosuppressants involved in drug–drug interactions.

  3. 2Severity of interaction: +++, severe interaction, use alternative drug if possible, otherwise monitor levels of immunosuppressant or potential toxic effects and modify dose accordingly; ++, moderate interaction, requires monitoring levels or potential toxicity, and may require modification of immunosuppressant dosing; +, minor interaction or does not have major toxicity; +/–, in vitro data and/or case reports have reported an interaction, but changes in immunosuppressive levels have not been consistently seen in clinical practice.

  4. 3Weight of evidence: A, very good evidence such as clinical trial, pharmacokinetic studies in volunteers or patients, many well-documented case reports, or biochemical evidence confirming interaction; B, good evidence such as several well-documented case reports; C, anecdotal experience, one or two case reports.

  5. 4Majority of in vitro and in vivo data show no interaction.

  6. 5No patient data reported. Manufacturer's data indicate interaction with CYP3A4 metabolism, which could affect CSA, TAC, SRL, EVR.

  7. 6Doxycycline and minocycline have no reported interaction with CSA, TAC, SRL or EVR.

  8. 7Product information for caspofungin recommends standard tacrolimus dose monitoring and appropriate tacrolimus dosage adjustments but a subsequent study in heart and lung transplant recipients did not find any significant changes in tacrolimus troughs or doses Ref. (37).

  9. 8NNRTIs = nonnucleoside reverse transcriptase inhibitors (DLV = delaviridine; EFV = efavirenz; ETR = etravirine; NVP = nevirapine). If NNRTI used in combination with protease inhibitor, will need to monitor drug levels closely as TAC and CSA as well as SRL and EVR dosing interval may need to be reduced.

  10. 9PIs = protease inhibitors (ATV = atazanavir; DRV = darunavir; FPV = fosamprenavir; IDV = indinavir; LPVr = lopinavir + ritonavir; NFV = nelfinavir; RTV = ritonavir; SQV = saquinavir; TPVr = tipranavir + ritonavir. All protease inhibitors inhibit metabolism of CSA, TAC, SRL, EVR. PIs “boosted” with RTV often require further reduction in immunosuppression dosage.

  11. 10Product information for tacrolimus notes contraindicated use with NFV.

  12. 11NRTIs = nucleoside reverse transcriptase inhibitors (AZT = zidovudine; D4T = stavudine). None of the NRTIs are expected to interact with CSA, TAC, SRL, EVR.

Antibacterials     
Fluoroquinolones     
OfloxacinCSA, TAC++[UPWARDS ARROW] Imm levelsChoose alternateB
CiprofloxacinCSA, TAC+/–May [UPWARDS ARROW] Imm levelsNo adjustment/consider monitoring Imm levelsB
LevofloxacinCSA+/–May [UPWARDS ARROW]CsANo adjustment/consider monitoring Imm levelsA
MoxifloxacinCSA, TAC, SRL, EVRNoneNo adjustmentB
Macrolides     
ErythromycinCSA, TAC, SRL, EVR+++[UPWARDS ARROW] Imm levelsAvoidA
ClarithromycinCSA, TAC, SRL, EVR+++[UPWARDS ARROW] Imm levelsAvoid/[DOWNWARDS ARROW] Imm by1/2A
TelithromycinCSA, TAC, SRL, EVR+++[UPWARDS ARROW] Imm levelsAvoidA
Azithromycin4CSA, TAC, SRL, EVR+/–[UPWARDS ARROW] Imm levelsNo adjustment/consider monitoring Imm levelsA
Rifamycins     
RifabutinCSA TAC, SRL, EVR++[DOWNWARDS ARROW] Imm levelsMonitor Imm LevelsA
Rifapentine5CSA, TAC, SRL, EVR, Prednisone++[DOWNWARDS ARROW] Imm levelsMonitor Imm LevelsN/A
RifampinCSA, TAC, SRL, EVR, MMF, ECMS+++[DOWNWARDS ARROW] Imm levelsAvoid/Monitor Imm LevelsA
Aminoglycosides     
GentamicinCSA, TAC+++Enhanced nephrotoxicityAvoid/Monitor Imm Levels and renal functionA
Tobramycin     
Amikacin     
Streptomycin     
Other antibacterials     
NafcillinCSA, TAC, SRL, EVR+[DOWNWARDS ARROW]Imm levelsMonitor Imm LevelsB
Quinupristin/DalfopristinCSA+++[UPWARDS ARROW] CsAMonitor Imm LevelsB
LinezolidMMF, ECMS, AZA++MyelosuppressionMonitor WBC and plateletsB
SulfonamidesMMF, ECMS, AZACSA, TAC++++MyelosuppressionNephrotoxicityMonitor WBC, hematocrit, platelets and renal functionB
Tetracycline6CSA, TAC, SRL, EVR+[UPWARDS ARROW]Imm LevelsMonitor Imm LevelsB
TigecyclineCSA+[UPWARDS ARROW]Imm LevelsMonitor Imm LevelsC
MetronidazoleCSA, TAC, SRL, EVR+/–May [UPWARDS ARROW]Imm LevelsNo adjustment/consider monitor levelsB
ChloramphenicolCSA, TAC, SRL, EVR++[UPWARDS ARROW]Imm Levels[DOWNWARDS ARROW]CSA or TAC by 25%B
(intravenous)     
ClindamycinCSA, TAC, SRL, EVR+/–May [DOWNWARDS ARROW]Imm levelsNo adjustment/consider monitor levelsC
Antimalarial     
Artemether5/LumefantrineCSA, TAC, SRL, EVR++[DOWNWARDS ARROW]Imm levelsMonitor Imm LevelsN/A
Antifungals     
Azoles     
KetoconazoleCSA, TAC, SRL, EVR+++[UPWARDS ARROW] Imm levelsAvoid/[DOWNWARDS ARROW]Imm by 1/2A
VoriconazoleCSA, TAC, SRL, EVR+++[UPWARDS ARROW] Imm levels[DOWNWARDS ARROW]CsA by 1/2, [DOWNWARDS ARROW]Tac by 2/3A
ItraconazoleCSA, TAC, SRL, EVR++[UPWARDS ARROW] Imm levelsMonitor Imm LevelsA
PosaconazoleCSA, TAC, SRL, EVR+++[UPWARDS ARROW] Imm levels[DOWNWARDS ARROW]CsA by 1/4, [DOWNWARDS ARROW]Tac by 2/3A
FluconazoleCSA, TAC, SRL, EVR++[UPWARDS ARROW] Imm levelsDose dependent [DOWNWARDS ARROW]CsA and Tac by 1/3A
ClotrimazoleCSA, TAC, SRL, EVR++[UPWARDS ARROW] Imm levelsMonitor Imm LevelsA
Echinocandins     
Caspofungin7TAC+/–May [DOWNWARDS ARROW]TAC levelsNoneB
 CSA++[UPWARDS ARROW] Caspofungin LevelsMonitor AST/ALTB
 MMF (no data on ECMS)NoneNoneN/A-product info
 No data on SRL, EVR    
MicafunginTAC, MMF, Prednisone (no data on ECMS)NoneNoneN/A-product info
 CSA++[DOWNWARDS ARROW] CSA levelsMonitor Imm LevelsA
 SRL (no data on EVR)++[UPWARDS ARROW]SRL levelsMonitor Imm LevelsN/A product info
AnidulafunginCSA+[UPWARDS ARROW] Anidulafungin levelsNoneA
 TACNo data on SRL, EVRNoneNoneA
Polyenes     
Amphotericin     
Lipid formulationCSA, TAC++NephrotoxicityMonitor Imm Levels and renal functionA
Amphotericins     
Antiviral agents     
Antiviral agents (non HIV)     
AcyclovirMMF, ECMS+/–[UPWARDS ARROW]ACV, [DOWNWARDS ARROW]MPANoneC
Intravenous acyclovirCSA, TAC+++NephrotoxicityMonitor renal functionA
ValacyclovirMMF, ECMS+/–[DOWNWARDS ARROW]MPANoneC
GanciclovirMMF, ECMS, AZA++NeutropeniaMonitor WBCB
ValganciclovirMMF, ECMS, AZA++NeutropeniaMonitor WBCB
FoscarnetCSA, TAC+++NephrotoxicityMonitor renal function, Ca, Mg,A
   [DOWNWARDS ARROW]Ca [DOWNWARDS ARROW]MgCNI levels, decrease foscarnet 
CidofovirCSA, TAC+++NephrotoxicityMonitor renal functionA
BoceprevirCSA, TAC, SRL, EVR+++[UPWARDS ARROW] Imm levelsImm dose reductions vary (see text)A
TelaprevirCSA, TAC, SRL, EVR, systemic prednisone and methylprednisolone+++[UPWARDS ARROW] Imm levelsImm dose reductions vary (see text)A
LeflunomideMMF, ECMS, AZA, SRL, EVR+++MyelosuppressionHold MMF, ECMS, AZA and monitor WBC, hematocrit and plateletsA
OseltamivirCSA, TAC, MMF+/–13% increase in TAC trough onlyMonitor Imm LevelsA
 SRLNone C
 No data with ECMS, EVR    
Zanamivir4CSA, TAC, SRL, EVRNoneNoneN/A-product info
 MMF, ECMS    
Antiretroviral agents     
NNRTIs8     
EFVCSA, TAC, SRL, EVR++[DOWNWARDS ARROW]CSA, [DOWNWARDS ARROW] TACMonitor Imm LevelsA
NVPCSA, TAC, SRL, EVR+/–May [DOWNWARDS ARROW] Imm levelsMonitor Imm LevelsN/A
ETR5CSA, TAC, SRL, EVR+/–May [DOWNWARDS ARROW] Imm levelsMonitor Imm LevelsN/A
DLV5CSA, TAC, SRL, EVR++[UPWARDS ARROW] Imm levelsMonitor Imm LevelsN/A
PIs9     
(ATV, DRV, FPV, IDV, LPVr, NFV10, RTV, SQV, TPVr)CSA, TAC, SRL, EVR not recommended for use with RTV-regimens+++[UPWARDS ARROW]CSACSA 25-50 mg dailyA
  +++[UPWARDS ARROW]TAC/SRL/EVRTAC 1 mg once or twice a weekA
    SRL 1 mg once or twice a weekA
    When using RTV-PI boosted regimenB
    TPVr interaction unpredictable 
NRTIs11     
AZTMMF/ECMS+In vitro antagonismNoneC
D4TMMF/ECMS+In vitro antagonismNoneC

Acknowledgments

  1. Top of page
  2. Introduction
  3. Interactions That Significantly Raise Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  4. Interactions That Significantly Decrease Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  5. Acknowledgments
  6. Disclosures
  7. References

This manuscript was modified from a previous guideline written by LD Thomas and Geraldine Miller published in the American Journal of Transplantation 2009;9(Suppl 4): S263–S266, and endorsed by American Society of Transplantation/Canadian Society of Transplantation.

Funding source: The authors have not accepted funding or support for preparation of this manuscript.

Disclosures

  1. Top of page
  2. Introduction
  3. Interactions That Significantly Raise Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  4. Interactions That Significantly Decrease Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  5. Acknowledgments
  6. Disclosures
  7. References

The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Dr. Trofe-Clark is a consultant for LexiComp, is a Transplant Medical Review Board Member for CMS, and attended a transplant pharmacy advisory board meeting for Novartis Pharmaceuticals.

References

  1. Top of page
  2. Introduction
  3. Interactions That Significantly Raise Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  4. Interactions That Significantly Decrease Calcineurin Inhibitor and mTOR Inhibitor Plasma Levels
  5. Acknowledgments
  6. Disclosures
  7. References
  • 1
    Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262274.
  • 2
    Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am J Transplant 2012; 12(Suppl 1): 1156.
  • 3
    Fishman JA. Infections in immunocompromised hosts and organ transplant recipients: Essentials. Liver Transpl 2011; 17(Suppl 3): S34S37.
  • 4
    Fishman JA, Issa NC. Infection in organ transplantation: Risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010; 24: 273283.
  • 5
    Glotzbecker B, Duncan C, Alyea E, 3rd, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: What every physician should know. Biol Blood Marrow Transplant 2012; 18: 9891006.
  • 6
    Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 2005; 5: 207217.
  • 7
    Rabie R, Mumtaz K, Renner EL. Efficacy of antiviral therapy for hepatitis C post liver transplant on cyclosporine versus tacrolimus: A systematic review and meta-analysis. Liver Transpl 2013; 19:3648.
  • 8
    Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 10751085.
  • 9
    Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002; 35: 5361.
  • 10
    Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: Incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88: 135141.
  • 11
    Nyman HA, Dowling TC, Hudson JQ, Peter WL, Joy MS, Nolin TD. Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: An opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2011; 3: 11301144.
  • 12
    Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106131.
  • 13
    Page RL, 2nd, Ruscin JM, Fish D, Lapointe M. Possible interaction between intravenous azithromycin and oral cyclosporine. Pharmacotherapy 2001; 21: 14361443.
  • 14
    Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: A case report. Nephron 1995; 70: 130.
  • 15
    Shullo MA, Schonder K, Teuteberg JJ. Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: A case report. Transplant Proc 2010; 42: 18701872.
  • 16
    Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 14411458.
  • 17
    Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation 2004; 77: 474475.
  • 18
    Gonzalez F, Espinoza M, Herrera P, et al. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial. Transplant Proc 2010; 42: 270272.
  • 19
    el-Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: Ten-year follow-up. Transplantation 2004; 77: 13711376.
  • 20
    El-Dahshan KF, Bakr MA, Donia AF, Badr Ael S, Sobh MA. Ketoconazole-tacrolimus coadministration in kidney transplant recipients: Two-year results of a prospective randomized study. Am J Nephrol 2006; 26: 293298.
  • 21
    Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: Review of the literature and clinical applications. Pharmacotherapy 2000; 20: 13351355.
  • 22
    Page RL, 2nd, Mueller SW, Levi ME, Lindenfeld J. Pharmacokinetic drug-drug interactions between calcineurin inhibitors and proliferation signal inhibitors with anti-microbial agents: Implications for therapeutic drug monitoring. J Heart Lung Transplant 2011; 30: 124135.
  • 23
    Pfizer Incorporated. VFEND I.V. (voriconazole for Injection); VFEND Tablets (voriconazole); VFEND (voriconazole for oral suspension), United States prescribing information, New York, NY, 2011.
  • 24
    Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: A pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008; 28: 719729.
  • 25
    Novartis Pharmaceuticals Corporation. Zortress (everolimus) tablets for oral use, United States prescribing information, East Hanover, NJ, 2012.
  • 26
    Billaud EM, Antoine C, Berge M, Abboud I, Lefeuvre S, Benammar M, et al. Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient. Clin Drug Investig 2009; 29: 481486.
  • 27
    Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, et al. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother 2008; 42: 17111716.
  • 28
    Schering Corporation. Noxafil (posaconazole) oral suspension for oral use,United States prescribing information, Kenilworth, NJ, 2011.
  • 29
    Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27: 825834.
  • 30
    Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009; 25: 701707.
  • 31
    Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: A drug interaction in kidney transplant patients. Clin Transplant 2001; 15: 9599.
  • 32
    Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. Ther Drug Monit 2005; 27: 587591.
  • 33
    Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 1991; 52: 10861087.
  • 34
    Choy M. Tacrolimus interaction with clotrimazole: A concise case report and literature review. P T 2010; 35: 568569.
  • 35
    Merck and Company, Inc. Cancidas (caspofungin) injection for intravenous use, United States prescribing information, Whitehouse Station, NJ, 2010.
  • 36
    Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004; 6: 110116.
  • 37
    Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 2008; 27: 16.
  • 38
    Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: A comparison. Drugs 2011; 71: 1141.
  • 39
    Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 10181024.
  • 40
    Astellas Pharma US Inc. Mycamine (micafungin) injection for intravenous use, United States prescribing information, Deerfield, IL, 2011.
  • 41
    Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 954960.
  • 42
    Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 227233.
  • 43
    Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007; 47: 305314.
  • 44
    Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363: 20042014.
  • 45
    Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 28162820.
  • 46
    Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hcv protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 16221630.
  • 47
    Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 16201628.
  • 48
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 2027.
  • 49
    Sam T, Tichy E, Emre S., Schilsky M.Pharmacokinetic effects of boceprevir co-administration on cyclosporine exposure in liver transplant recipients. Am J Transplant 2012; 12(Suppl 3): 430 (Abstract 1370).
  • 50
    de Oliveira Pereira A, Shin H, Safdar A, et al. Post liver transplant therapy with telaprevir for recurrent hepatitis C. Am J Transplant 2012; 12 (Suppl 3): 430 (Abstract 1369).
  • 51
    Pungpapong S, Murphy J, Henry T, et al. Iniital experience utilizing telaprevir with peginterferon and ribavirin for treatment of hepatitis C genotype 1 after liver transplantation. Am J Transplant 2012; 12(Suppl 3): 430 (Abstract 1367).
  • 52
    Rogers C, Stevens D, Kim M, Ghaziani T, Malik R, Curry M. Telaprevir can be used safely with concomitant tacrolimus in the post-transplant setting. Am J Transplant 2012; 12(Suppl 3): 431 (Abstract 1372).
  • 53
    Burton JR, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: Virologic response, safety, and tolerability. Am J Transplant 2012; 12(Suppl 3): 188 (Abstract LB 01).
  • 54
    Ha YE, Joo EJ, Park SY, et al. Tacrolimus as a risk factor for tuberculosis and outcome of treatment with rifampicin in solid organ transplant recipients. Transpl Infect Dis. 2012; 14: 626634.
  • 55
    Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: What everyone should know. Curr Opin Nephrol Hypertens 2009; 18: 404411.
  • 56
    Lopez-Montes A, Gallego E, Lopez E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis 2004; 44: e59e63.
  • 57
    Chenhsu RY, Loong CC, Chou MH, Lin MF, Yang WC. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacother 2000; 34: 2731.
  • 58
    Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shumway NE. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39: 313314.
  • 59
    Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002; 36: 981985.
  • 60
    Ngo BT, Pascoe M, Khan D. Drug interaction between rifampicin and sirolimus in transplant patients. Saudi J Kidney Dis Transpl 2011; 22: 112115.
  • 61
    Bhaloo S, Prasad GV. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: A case report. Transplant Proc 2003; 35: 24492451.
  • 62
    Naesens M, Kuypers DR, Streit F, et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006; 80: 509521.
  • 63
    Genetech Incorporated. Mycophenolate mofetil (CellCept) capsules, tablets and oral suspension and mycophenolate mofetil hydrochloride for injection, United States prescribing information. South San Francisco, CA, 2012.
  • 64
    Novartis Pharmaceuticals Corporation. Mycophenolic acid delayed release tablets as mycophenolate sodium (Myfortic) for oral use, United States prescribing information. East Hanover, NJ, 2010.
  • 65
    Novartis Pharmaceuticals Corporation. Coartem (artemether/lumefantrine) tablets for oral use, United States prescribing information. East Hanover, NJ, 2010.